|
1
|
Wild S, Roglic G, Green A, Sicree R and
King H: Global prevalence of diabetes: Estimates for the year 2000
and projections for 2030. Diabetes Care. 27:1047–1053.
2004.PubMed/NCBI View Article : Google Scholar
|
|
2
|
American Diabetes Association. Standards
of medical care in diabetes - 2011. Diabetes Care. 34 (Suppl
1):S11–S61. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hajhosseiny R, Khavandi K, Jivraj N,
Mashayekhi S, Goldsmith DJ and Malik RA: Have we reached the limits
for the treatment of diabetic nephropathy? Expert Opin Investig
Drugs. 23:511–522. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Heart Outcomes Prevention Evaluation Study
Investigators. Effects of ramipril on cardiovascular and
microvascular outcomes in people with diabetes mellitus: Results of
the HOPE study and MICRO-HOPE substudy. Lancet. 355:253–259.
2000.PubMed/NCBI
|
|
5
|
Hu R and Yang Z: Study on effect of the
combined treatment of enalapril and amlodipine in elderly diabetic
patients with hypertension. Diabetes New World. 24:6–7. 2014.(In
Chinese).
|
|
6
|
Melbourne Diabetic Nephropathy Study
Group. Comparison between perindopril and nifedipine in
hypertensive and normotensive diabetic patients with
microalbuminuria. BMJ. 302:210–216. 1991.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jerums G, Allen TJ, Campbell DJ, Cooper
ME, Gilbert RE, Hammond JJ, O'Brien RC, Raffaele J and Tsalamandris
C: Melbourne Diabetic Nephropathy Study Group. Long-term
renoprotection by perindopril or nifedipine in non-hypertensive
patients with Type 2 diabetes and microalbuminuria. Diabet Med.
21:1192–1199. 2004.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fogari R, Preti P, Zoppi A, Rinaldi A,
Corradi L, Pasotti C, Poletti L, Marasi G, Derosa G, Mugellini A,
et al: Effects of amlodipine fosinopril combination on
microalbuminuria in hypertensive type 2 diabetic patients. Am J
Hypertens. 15:1042–1049. 2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Luque Otero M and Martell Claros N: Study
Investigators Group. Manidipine versus enalapril monotherapy in
patients with hypertension and type 2 diabetes mellitus: A
multicenter, randomized, double-blind, 24-week study. Clin Ther.
27:166–173. 2005.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Higgins J and Green S: Cochrane Handbook
for Systemic Reviews of Interventions. Version 5.1. The Cochrane
Collaboration, 2011. urihttps://handbook-5-1.cochrane.orgsimplehttps://handbook-5-1.cochrane.org.
Accessed June 1, 2020.
|
|
11
|
Higgins J, Altman D and Sterne J: Cochrane
Statistical Methods Group and the Cochrane Bias Methods Group
(eds): Chapter 8: Assessing risk of bias in included studies. In:
Cochrane Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.
urihttps://handbook-5-1.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htmsimplehttps://handbook-5-1.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm.
|
|
12
|
Rachmani R, Lidar M, Brosh D, Levi Z and
Ravid M: Oxidation of low-density lipoprotein in normotensive type
2 diabetic patients. Comparative effects of enalapril versus
nifedipine: A randomized cross-over over study. Diabetes Res Clin
Pract. 48:139–145. 2000.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Fogari R, Zoppi A, Corradi L, Poletti L,
Pasotti M, Fogari E and Mugellini A: Long-term effects of
amlodipine versus fosinopril on microalbuminuria in elderly
hypertensive patients with type 2 diabetes mellitus. Curr Ther Res
Clin Exp. 61:163–173. 2000.
|
|
14
|
Shiba T, Inoue M, Tada H, Hayashi Y, Okuda
Y, Fujita R, Makino F, Takahasi C, Kageyama S, Kitamura S, et al:
Delapril versus manidipine in hypertensive therapy to halt the
type-2-diabetes-mellitus-associated nephropathy. Diabetes Res Clin
Pract. 47:97–104. 2000.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gao Z and Chang J: Effects of enalapril
combined with Levamlodipine on type 2 diabetic nephropathy. J Med
Theory Practice. 1:12–14. 2006.(In Chinese).
|
|
16
|
Chan JC, Ko GTC, Leung DHY, Cheung RC,
Cheung MY, So WY, Swaminathan R, Nicholls MG, Critchley JA and
Cockram CS: Long-term effects of angiotensin-converting enzyme
inhibition and metabolic control in hypertensive type 2 diabetic
patients. Kidney Int. 57:590–600. 2000.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Baba S: J-MIND Study Group. Nifedipine and
enalapril equally reduce the progression of nephropathy in
hypertensive type 2 diabetics. Diabetes Res Clin Pract. 54:191–201.
2001.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Dalla Vestra M, Pozza G, Mosca A, Grazioli
V, Lapolla A, Fioretto P and Crepaldi G: Effect of lercanidipine
compared with ramipril on albumin excretion rate in hypertensive
type 2 diabetic patients with microalbuminuria: DIAL study
(diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr
Metab. 17:259–266. 2004.PubMed/NCBI
|
|
19
|
Jerums G, Allen TJ, Campbell DJ, Cooper
ME, Gilbert RE, Hammond JJ, Raffaele J and Tsalamandris C:
Long-term comparison between perindopril and nifedipine in
normotensive patients with type 1 diabetes and microalbuminuria. Am
J Kidney Dis. 37:890–899. 2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wakahara S, Konoshita T, Mizuno S,
Motomura M, Aoyama C, Makino Y, Kato N, Koni I and Miyamori I:
Synergistic expression of angiotensin-converting enzyme (ACE) and
ACE2 in human renal tissue and confounding effects of hypertension
on the ACE to ACE2 ratio. Endocrinology. 148:2453–2457.
2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ogihara T, Kikuchi K, Matsuoka H, Fujita
T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, et al:
Japanese Society of Hypertension Committee: The Japanese Society of
Hypertension Guidelines for the Management of Hypertension (JSH
2009). Hypertens Res. 32:3–107. 2009.PubMed/NCBI
|
|
22
|
American Diabetes Association. Standards
of medical care for patients with diabetes mellitus. Diabetes Care.
26 (Suppl 1):S33–S50. 2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Poortmans JR and Ouchinsky M: Glomerular
filtration rate and albumin excretion after maximal exercise in
aging sedentary and active men. J Gerontol A Biol Sci Med Sci.
61:1181–1185. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Takahara A: Cilnidipine: A new generation
Ca channel blocker with inhibitory action on sympathetic
neurotransmitter release. Cardiovasc Ther. 27:124–139.
2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Catterall WA: Structure and regulation of
voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol.
16:521–555. 2000.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ertel EA, Campbell KP, Harpold MM, Hofmann
F, Mori Y, Perez-Reyes E, Schwartz A, Snutch TP, Tanabe T,
Birnbaumer L, et al: Nomenclature of voltage-gated calcium
channels. Neuron. 25:533–535. 2000.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Agardh CD, Garcia-Puig J, Charbonnel B,
Angelkort B and Barnett AH: Greater reduction of urinary albumin
excretion in hypertensive type II diabetic patients with incipient
nephropathy by lisinopril than by nifedipine. J Hum Hypertens.
10:185–192. 1996.PubMed/NCBI
|
|
28
|
Ruggenenti P, Mosconi L, Bianchi L,
Cortesi L, Campana M, Pagani G, Mecca G and Remuzzi G: Long-term
treatment with either enalapril or nitrendipine stabilizes
albuminuria and increases glomerular filtration rate in
non-insulin-dependent diabetic patients. Am J Kidney Dis.
24:753–761. 1994.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Velussi M, Brocco E, Frigato F, Zolli M,
Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, et
al: Effects of cilazapril and amlodipine on kidney function in
hypertensive NIDDM patients. Diabetes. 45:216–222. 1996.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Estacio RO, Jeffers BW, Gifford N and
Schrier RW: Effect of blood pressure control on diabetic
microvascular complications in patients with hypertension and type
2 diabetes. Diabetes Care. 23 (Suppl 2):B54–B64. 2000.PubMed/NCBI
|
|
31
|
Loutzenhiser R and Epstein M: Effects of
calcium antagonists on renal hemodynamics. Am J Physiol.
249:F619–F629. 1985.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gansevoort RT, Apperloo AJ, Heeg JE, de
Jong PE and de Zeeuw D: The antiproteinuric effect of
antihypertensive agents in diabetic nephropathy. Arch Intern Med.
152:2137–2139. 1992.PubMed/NCBI
|
|
33
|
Ono T, Liu N, Kusano H, Nogaki F, Makino
T, Muso E and Sasayama S: Broad antiproliferative effects of
benidipine on cultured human mesangial cells in cell cycle phases.
Am J Nephrol. 22:581–586. 2002.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Fogari R, Zoppi A, Mugellini A, Lusardi P,
Destro M and Corradi L: Effect of benazepril plus amlodipine vs
benazepril alone on urinary albumin excretion in hypertensive
patients with type ii diabetes and microalbuminuria. Clin Drug
Investig. 13 (Suppl 1):50–55. 1997.
|
|
35
|
Shigihara T, Sato A, Hayashi K and Saruta
T: Effect of combination therapy of angiotensin-converting enzyme
inhibitor plus calcium channel blocker on urinary albumin excretion
in hypertensive microalbuminuric patients with type II diabetes.
Hypertens Res. 23:219–226. 2000.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhao J: Therapy effect observation of
Levamlodipine combined with Benazepril in the treatment of 22 cases
of type 2 diabetic nephropathy with hypertension patients. Shandong
Medicine: 53-54, 2010.
|
|
37
|
Noto H, Goto A, Tsujimoto T and Noda M:
Effect of calcium channel blockers on incidence of diabetes: A
meta-analysis. Diabetes Metab Syndr Obes. 6:257–261.
2013.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Abe H, Mita T, Yamamoto R, Komiya K,
Kawaguchi M, Sakurai Y, Shimizu T, Ohmura C, Ikeda F, Kawamori R,
et al: Comparison of effects of cilnidipine and azelnidipine on
blood pressure, heart rate and albuminuria in type 2 diabetics with
hypertension: A pilot study. J Diabetes Investig. 4:202–205.
2013.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Konoshita T, Makino Y, Kimura T, Fujii M,
Morikawa N, Wakahara S, Arakawa K, Inoki I, Nakamura H and Miyamori
I: Genomic Disease Outcome Consortium (G-DOC) Study Investigators.
A crossover comparison of urinary albumin excretion as a new
surrogate marker for cardiovascular disease among 4 types of
calcium channel blockers. Int J Cardiol. 166:448–452.
2013.PubMed/NCBI View Article : Google Scholar
|
